Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Not listed Phase 2 Interventional

Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients

ClinicalTrials.gov ID: NCT00081783

Public ClinicalTrials.gov record NCT00081783. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Sep 8, 2026, 8:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of Xcellerated T CellsTM in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma (NHL)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase II single arm study of a novel T cell immunotherapy in patients with indolent non-Hodgkin's lymphoma (NHL). Eligible patients will have relapsed or refractory disease after receiving at least one and no more than four prior regimens. Patients will receive Xcellerated T CellsTM, an ex vivo activated and expanded autologous T cell product, in an attempt to enhance immune responses with anti-tumor activity. The primary endpoint of the study is to evaluate the efficacy of Xcellerated T Cells in patients with indolent NHL. Secondary endpoints are to evaluate the safety of the therapy in this patient population, and to evaluate changes in the number and phenotype of T- and B-lymphocytes, as well as changes in the T cell receptor repertoire, hemoglobin levels, platelet counts and quantitative immunoglobulin levels. In a subset of patients, fine-needle aspirates of malignant lymph nodes will be performed to assess changes in the lymphocyte composition and phenotype. Bone marrow aspirates will be similarly evaluated. Finally, anti-tumor immune responses will be evaluated in patients amenable to biopsy of enlarged lymph nodes.

Study identification

NCT ID
NCT00081783
Recruitment status
Not listed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Xcyte Therapies
Industry
Enrollment
40 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 29, 2004
Primary completion
Not listed
Completion
Not listed
Last update posted
Jun 23, 2005

Started 2004

United States locations

U.S. sites
18
U.S. states
12
U.S. cities
16
Facility City State ZIP Site status
California Cancer Care Greenbrae California 94904 Recruiting
University of Southern California Los Angeles California 90033 Not yet recruiting
University of California, San Diego San Diego California 92093 Recruiting
Sharp Memorial Hospital San Diego California 92123 Recruiting
University of California, San Francisco San Francisco California 94143 Recruiting
Rocky Mountain Cancer Centers Denver Colorado 80218 Recruiting
Atlanta Cancer Care Roswell Georgia 30342 Recruiting
Johns Hopkins University Baltimore Maryland 21231 Recruiting
Center for Cancer & Blood Disorders Bethesda Maryland 20817 Recruiting
Dana-Farber Cancer Institute Boston Massachusetts 02115 Recruiting
Washington University St Louis Missouri 63110 Recruiting
Cancer Institute of New Jersey New Brunswick New Jersey 08903 Recruiting
Ohio State University Columbus Ohio 43210 Recruiting
Oregon Health Sciences University Portland Oregon 97239 Recruiting
Cancer Centers of the Carolinas Greenville South Carolina 29605 Recruiting
MD Anderson Cancer Center Houston Texas 77030 Recruiting
Swedish Cancer Institute Seattle Washington 98104 Recruiting
Virginia Mason Seattle Washington 98111 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Recently updated Non-Hodgkin's Lymphoma trials

Other public records listing Non-Hodgkin's Lymphoma. Sorted by last update posted; newest first. Not a recommendation.

All Non-Hodgkin's Lymphoma trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00081783, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 23, 2005 · Synced Sep 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00081783 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →